Utilizing the protein corona around silica nanoparticles for dual drug loading and release.

A protein corona forms spontaneously around silica nanoparticles (SNPs) in serum-containing media. To test whether this protein corona can be utilized for the loading and release of anticancer drugs we incorporated the hydrophilic doxorubicin, the hydrophobic meloxicam as well as their combination in the corona around SNPs. The application of corona-covered SNPs to osteosarcoma cells revealed that drug-free particles did not affect the cell viability. In contrast, SNPs carrying a protein corona with doxorubicin or meloxicam lowered the cell proliferation in a concentration-dependent manner. In addition, these particles had an even greater antiproliferative potential than the respective concentrations of free drugs. The best antiproliferative effects were observed for SNPs containing both doxorubicin and meloxicam in their corona. Co-localization studies revealed the presence of doxorubicin fluorescence in the nucleus and lysosomes of cells exposed to doxorubicin-containing coated SNPs, suggesting that endocytotic uptake of the SNPs facilitates the cellular accumulation of the drug. Our data demonstrate that the protein corona, which spontaneously forms around nanoparticles, can be efficiently exploited for loading the particles with multiple drugs for therapeutic purposes. As drugs are efficiently released from such particles they may have a great potential for nanomedical applications.

[1]  Jordi Arbiol,et al.  Induced shape controllability by tailored precursor design in thermal and microwave-assisted synthesis of $$\mathrm{Fe}_{3}\mathrm{O}_{4}$$Fe3O4 nanoparticles , 2015 .

[2]  L. Treccani,et al.  Amino acid-catalyzed seed regrowth synthesis of photostable high fluorescent silica nanoparticles with tunable sizes for intracellular studies , 2015, Journal of Nanoparticle Research.

[3]  L. Treccani,et al.  Modulation of Silica Nanoparticle Uptake into Human Osteoblast Cells by Variation of the Ratio of Amino and Sulfonate Surface Groups: Effects of Serum , 2015, ACS applied materials & interfaces.

[4]  Hesham A El-Beshbishy,et al.  Modulatory effects of meloxicam on cardiotoxicity and antitumor activity of doxorubicin in mice , 2014, Cancer Chemotherapy and Pharmacology.

[5]  Wolfgang J. Parak,et al.  Protein corona formation around nanoparticles – from the past to the future , 2014 .

[6]  P. Netti,et al.  Effect of silica nanoparticles with variable size and surface functionalization on human endothelial cell viability and angiogenic activity , 2014, Journal of Nanoparticle Research.

[7]  Edouard C. Nice,et al.  Differential roles of the protein corona in the cellular uptake of nanoporous polymer particles by monocyte and macrophage cell lines. , 2013, ACS nano.

[8]  S. Ghosh,et al.  Gold nanoparticle-protein agglomerates as versatile nanocarriers for drug delivery. , 2013, Small.

[9]  James Chen Yong Kah,et al.  Optimizing the properties of the protein corona surrounding nanoparticles for tuning payload release. , 2013, ACS nano.

[10]  Luis M Liz-Marzán,et al.  Physicochemical properties of protein-coated gold nanoparticles in biological fluids and cells before and after proteolytic digestion. , 2013, Angewandte Chemie.

[11]  H. Iwahashi,et al.  Cellular effects of manufactured nanoparticles: effect of adsorption ability of nanoparticles , 2013, Archives of Toxicology.

[12]  Philip M. Kelly,et al.  Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. , 2013, Nature nanotechnology.

[13]  K. Dawson,et al.  Biomolecular Coronas Provide the Biological Identity of Nanomaterials , 2017 .

[14]  Christine K Payne,et al.  Nanoparticle surface charge mediates the cellular receptors used by protein-nanoparticle complexes. , 2012, The journal of physical chemistry. B.

[15]  James Chen Yong Kah,et al.  Exploiting the protein corona around gold nanorods for loading and triggered release. , 2012, ACS nano.

[16]  Iseult Lynch,et al.  Designing the nanoparticle-biomolecule interface for "targeting and therapeutic delivery". , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[17]  W. Peukert,et al.  Impact of the nanoparticle-protein corona on colloidal stability and protein structure. , 2012, Langmuir : the ACS journal of surfaces and colloids.

[18]  Andrzej S Pitek,et al.  Reversible versus irreversible binding of transferrin to polystyrene nanoparticles: soft and hard corona. , 2012, ACS nano.

[19]  Kanlaya Prapainop,et al.  A chemical approach for cell-specific targeting of nanomaterials: small-molecule-initiated misfolding of nanoparticle corona proteins. , 2012, Journal of the American Chemical Society.

[20]  K. Dawson,et al.  Experimental and theoretical comparison of intracellular import of polymeric nanoparticles and small molecules: toward models of uptake kinetics. , 2011, Nanomedicine : nanotechnology, biology, and medicine.

[21]  Guangjun Nie,et al.  Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. , 2011, Biomaterials.

[22]  R. Zhou,et al.  Binding of blood proteins to carbon nanotubes reduces cytotoxicity , 2011, Proceedings of the National Academy of Sciences.

[23]  Y. Yue,et al.  Protease-promoted drug delivery using peptide-functionalized gold nanoparticles , 2011 .

[24]  M. Mahmoudi,et al.  Protein-nanoparticle interactions: opportunities and challenges. , 2011, Chemical reviews.

[25]  Warren C W Chan,et al.  Effect of gold nanoparticle aggregation on cell uptake and toxicity. , 2011, ACS nano.

[26]  Kirsten Sandvig,et al.  Endocytosis and intracellular transport of nanoparticles: Present knowledge and need for future studies , 2011 .

[27]  Hicham A. Chibli,et al.  Ultrasmall gold-doxorubicin conjugates rapidly kill apoptosis-resistant cancer cells. , 2011, Bioconjugate chemistry.

[28]  Iseult Lynch,et al.  Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles. , 2011, Journal of the American Chemical Society.

[29]  M. Al-Rawi,et al.  Uptake and intracellular localization of submicron and nano-sized SiO2 particles in HeLa cells , 2011, Archives of Toxicology.

[30]  Ying Liu,et al.  Surface chemistry and aspect ratio mediated cellular uptake of Au nanorods. , 2010, Biomaterials.

[31]  M. Epple,et al.  Gold nanoparticles: dispersibility in biological media and cell-biological effect , 2010 .

[32]  Albert Duschl,et al.  Time evolution of the nanoparticle protein corona. , 2010, ACS nano.

[33]  Sunho Park,et al.  Enhancement of in vitro translation by gold nanoparticle--DNA conjugates. , 2010, ACS nano.

[34]  Amit Jain,et al.  The intracellular drug delivery and anti tumor activity of doxorubicin loaded poly(gamma-benzyl L-glutamate)-b-hyaluronan polymersomes. , 2010, Biomaterials.

[35]  Iseult Lynch,et al.  What the cell "sees" in bionanoscience. , 2010, Journal of the American Chemical Society.

[36]  E. Barcia,et al.  Effective antiproliferative effect of meloxicam on prostate cancer cells: development of a new controlled release system. , 2010, International journal of pharmaceutics.

[37]  Indrajit Roy,et al.  In vivo biodistribution and clearance studies using multimodal organically modified silica nanoparticles. , 2010, ACS nano.

[38]  Wolfgang J Parak,et al.  Intracellular processing of proteins mediated by biodegradable polyelectrolyte capsules. , 2009, Nano letters.

[39]  Brahim Lounis,et al.  Cathepsin L digestion of nanobioconjugates upon endocytosis. , 2009, ACS nano.

[40]  L. Deng,et al.  Synthesis and characterization of functionalized rhodamine B-doped silica nanoparticles , 2009 .

[41]  Iseult Lynch,et al.  Protein-nanoparticle interactions: What does the cell see? , 2009, Nature nanotechnology.

[42]  T. Xia,et al.  Understanding biophysicochemical interactions at the nano-bio interface. , 2009, Nature materials.

[43]  Parag Aggarwal,et al.  Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. , 2009, Advanced drug delivery reviews.

[44]  Kenneth A. Dawson,et al.  Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts , 2008, Proceedings of the National Academy of Sciences.

[45]  J. Inazawa,et al.  Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. , 2008, Cancer research.

[46]  Sara Linse,et al.  The nanoparticle-protein complex as a biological entity; a complex fluids and surface science challenge for the 21st century. , 2007, Advances in colloid and interface science.

[47]  N. Ishiguro,et al.  Synergistic effects of meloxicam and conventional cytotoxic drugs in human MG-63 osteosarcoma cells. , 2007, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[48]  Kemin Wang,et al.  Noninvasive monitoring of intracellular pH change induced by drug stimulation using silica nanoparticle sensors , 2007, Analytical and bioanalytical chemistry.

[49]  Sara Linse,et al.  Understanding the nanoparticle–protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles , 2007, Proceedings of the National Academy of Sciences.

[50]  E. Furth,et al.  Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster , 2006, Nature Genetics.

[51]  Sevim Z. Erhan,et al.  A New Polymer–Lipid Hybrid Nanoparticle System Increases Cytotoxicity of Doxorubicin Against Multidrug-Resistant Human Breast Cancer Cells , 2006, Pharmaceutical Research.

[52]  M. Egerbacher,et al.  Antineoplastic effect of the cyclooxygenase inhibitor meloxicam on canine osteosarcoma cells. , 2006, Research in veterinary science.

[53]  A. Pawar,et al.  Low density multiparticulate system for pulsatile release of meloxicam. , 2006, International journal of pharmaceutics.

[54]  M. Freedman,et al.  Adenovirus-mediated p53 gene therapy in osteosarcoma cell lines: sensitization to cisplatin and doxorubicin , 2006, Cancer Gene Therapy.

[55]  N. Ishiguro,et al.  Meloxicam inhibits osteosarcoma growth, invasiveness and metastasis by COX-2-dependent and independent routes. , 2006, Carcinogenesis.

[56]  M. Skalicky,et al.  In vitro effects of meloxicam with or without doxorubicin on canine osteosarcoma cells. , 2006, Journal of veterinary pharmacology and therapeutics.

[57]  A. Bottoni,et al.  Cyclooxygenase-2 inhibitors reverse chemoresistance phenotype in medullary thyroid carcinoma by a permeability glycoprotein-mediated mechanism. , 2005, The Journal of clinical endocrinology and metabolism.

[58]  Jui‐I Chao,et al.  Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells. , 2005, Biochemical pharmacology.

[59]  Sonu Bhatia,et al.  Mechanism of interaction of the non-steroidal antiinflammatory drugs meloxicam and nimesulide with serum albumin. , 2005, Journal of pharmaceutical and biomedical analysis.

[60]  Soo-Jeong Lim,et al.  Cyclooxygenase-independent down-regulation of multidrug resistance–associated protein-1 expression by celecoxib in human lung cancer cells , 2005, Molecular Cancer Therapeutics.

[61]  Omid C. Farokhzad,et al.  Nanoparticle-Aptamer Bioconjugates , 2004, Cancer Research.

[62]  S. Nie,et al.  In vivo cancer targeting and imaging with semiconductor quantum dots , 2004, Nature Biotechnology.

[63]  Tae Gwan Park,et al.  Folate receptor targeted biodegradable polymeric doxorubicin micelles. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[64]  M. Singh,et al.  Evaluation of An Aerosolized Selective COX-2 Inhibitor as a Potentiator of Doxorubicin in a Non-Small-Cell Lung Cancer Cell Line , 2003, Pharmaceutical Research.

[65]  K. Janes,et al.  Chitosan nanoparticles as delivery systems for doxorubicin. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[66]  T. Park,et al.  Biodegradable polymeric micelles composed of doxorubicin conjugated PLGA-PEG block copolymer. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[67]  P. Workman,et al.  The efflux of anthracyclines in multidrug-resistant cell lines. , 1993, Biochemical pharmacology.

[68]  N. Pimpha,et al.  Preparation of folate-conjugated pluronic F127/chitosan core-shell nanoparticles encapsulating doxorubicin for breast cancer treatment , 2012 .

[69]  L. Treccani,et al.  Orientation of human osteoblasts on hydroxyapatite-based microchannels. , 2012, Acta biomaterialia.

[70]  M. Gottesman.  Mechanisms of cancer drug resistance. , 2002, Annual review of medicine.